ArticleRSC advances2022

Discovery of Cobimetinib as a novel A-FABP inhibitor using machine learning and molecular docking-based virtual screening.

Shilun Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.